PE - anti Human CD22 - HIB22

PE - anti Human CD22 - HIB22

Catalog Number:
A001109275IMM
Mfr. No.:
22PE-100T
Price:
$512
  • Size:
    100 test
    Quantity:
    Add to Cart:
      • Overview
        • This antibody reacts with the CD22-antigen, which is expressed on human B lymphocytes. CD22 is expressed in the cytoplasm of virtually all B cells except plasma cells. CD45RO antigen on T cells and CD75 antigen on B cells have been identified as ligands for CD22. CD22 has been reported to participate in B-cell activation and also as an adhesion molecule. Although the immunobiology of this antigen has not been fully elucidated, reports indicate that ligation of CD22 induces constitutive internalization of the molecule followed by complete degradation.

          Please contact us at for specific academic pricing.

      • Properties
        • Isotype
          IgG1
          Reactivity
          human
          Clone
          HIB22
          Immunogen
          Hairy Cell Leukemia cells
          Conjugate
          PE
          Storage
          Store in the dark at 2-8 °C
          Concentration
          Please refer to the Certificate of Analysis for the lot-specific concentration.
          Molecular Weight
          130 - 140 kDa
          Regulatory Status
          CE Marking
          Antigen
          B-cell receptor CD22, B-lymphocyte cell adhesion molecule (BL-CAM), Sialic acid-binding Ig-like lectin 2 (Siglec-2), T-cell surface antigen Leu-14, SIGLEC-2, SIGLEC2, Lyb8 (Gene ID:933)

          * For research use only.

      • Applications
        • Application
          Flow Cytometry
          Application Description
          CD22, clone HIB22 is a mAb intended for identification/enumeration of B cells subsets, so much mature as late pro- and early pre-B cells by FCM. This reagent is effective for direct IF staining of human tissue for FCM analysis using ≤1 μg/106 cells.
      • Reference

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.